Scaling up for High Dose Delivery to the Lungs

The use of dry powder inhalers (DPIs) is expanding beyond asthma and chronic obstructive disease (COPD) into new therapeutic targets that include pulmonary arterial hypertension, idiopathic pulmonary fibrosis, anti-emetics, anti-diabetic, antivirals and orally inhaled vaccines and antibiotics. Recent product launches together with the noticeably strong DPI pipeline on the non-asthma, non-COPD market1 provide evidence of this expansion. The growing interest in delivering anti-virals, antibiotics, vaccines, peptides or other drugs systemically via the lung in a single or a short-term treatment, has fueled the development of inhalers which comprise: